ADP-Rezeptor-Antagonisten: neue Erkenntnisse zur Therapie und Prophylaxe der ischämischen Herzerkrankung

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Deutsche Medizinische Wochenschrift

• Publication date

  2011-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0031-1281533PMID 21713722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.

  2011cited by this paper
• The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Intravenous platelet blockade with cangrelor during PCI.

  2009cited by this paper
• Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Cytochrome P 450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Clinical overview of promising nonthienopyridine antiplatelet agents.

  2008cited by this paper
• Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

  2008cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

  2007cited by this paper
• Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

  2007cited by this paper
• Aspirin and clopidogrel resistance: an emerging clinical entity.

  2006cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

  2006cited by this paper
• Aspirin and clopidogrel resistance: an emerging clinical entity.

  2006cited by this paper
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

  2005cited by this paper
• Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

  2005cited by this paper
• For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• Evidence for Two Distinct G-protein-coupled ADP Receptors Mediating Platelet Activation

  1999cited by this paper
• The P2Y1 receptor, necessary but not sufficient to support full ADP‐induced platelet aggregation, is not the target of the drug clopidogrel

  1998cited by this paper
• Signaling through G Proteins in Platelets: to the Integrins and Beyond

  1997cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

  1992cited by this paper
• Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

  1990cited by this paper
• The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.

  1989cited by this paper
• A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

  1989cited by this paper

• Effect of the Flavonol Quercetin on Human Platelet Function: A Review

  2015cites this paper